Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990, SHE:002422) recorded a profit attributable to equity holders of 388 million yuan for the first half, compared with an attributable loss of 145.2 million yuan a year prior.
Earnings per share stood at 1.6639 yuan, whereas the company had posted a loss per share of 0.6371 yuan previously, according to a Monday Hong Kong bourse filing.
Revenue rose 2.9% to 978.3 million yuan from 950.4 million yuan in the year-ago period.